We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
News

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration
News

Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Pacific Biomarkers, WuXi PharmaTech Announce Biomarker Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.

"We are very pleased to reach this agreement with Pacific Biomarkers, which broadens WuXi's biomarker capabilities in support of our clients' clinical development," said Dr. Ge Li, Chairman and CEO of WuXi PharmaTech. "Biomarkers are a new and important tool in the development of personalized medicines for many serious diseases."

"Partnering with WuXi enables us to realize considerable value in our biomarker assets," said Ronald Helm, CEO of Pacific Biomarkers. "This agreement will allow us to support a broader spectrum of companies developing medicines in Asia with special emphasis on clinical trials performed in China."

Advertisement